Core Viewpoint - The announcement from the company indicates that the oral FASN inhibitor, denifasertib (ASC40), has successfully met all primary, key secondary, and secondary endpoints in its Phase III clinical trial for the treatment of moderate to severe acne vulgaris, demonstrating significant statistical and clinical improvements compared to placebo [1] Group 1 - Denifasertib achieved a treatment success percentage of 18.6% after placebo adjustment, which is significantly higher than the FDA-approved treatments: sarecycline (9.4%) and doxycycline (6.7%), showing improvements of 98% and 178% respectively [1] - The efficacy of denifasertib also surpassed that of the FDA-approved clascoterone cream (11.6%) by 60% [1] - The drug exhibited good safety and tolerability characteristics throughout the trial [1]
歌礼制药：ASC40痤疮III期试验达到所有终点